Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

@inproceedings{McDaniel2012MolecularAO,
  title={Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies},
  author={Jessica M. McDaniel and Javier Pinilla-Ibarz and P. K. Epling-Burnette},
  booktitle={Advances in hematology},
  year={2012}
}
The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), as well as in drug combinations for some solid tumors and mantle cell lymphoma (MCL). Although treatment with lenalidomide has translated into a… CONTINUE READING
20 Citations
87 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 87 references

Lenalidomide repairs suppressed T cell immunological synapse formation in follicular lymphoma

  • A. G. Ramsay, A. J. Clear, R. Fatah, J. G. Gribben
  • Blood, vol. 112, 2008, Abstract no. 885.
  • 2008
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…